Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cangene Advances Alzheimer's Disease Research with Technology Developed at UBC

Published: Monday, September 16, 2013
Last Updated: Monday, September 16, 2013
Bookmark and Share
New technology targeting Alzheimer's Disease licensed to Cangene Corporation.

A truly made-in-Canada treatment for one of the world's most devastating diseases could be closer to patients thanks to a new technology targeting Alzheimer's Disease developed at The University of British Columbia (UBC) and licensed to Cangene Corporation (Cangene).

Following the successful research collaboration with the inventor, Dr. Neil Cashman at UBC, Cangene recently obtained commercial rights to the technology platform and plans to advance the program in its pipeline to explore treatments for Alzheimer's Disease, a significant unmet medical need with an increasing burden on health-care systems.

Cangene, with core competencies in the development and commercialization of biologic therapeutics, has established a strong pipeline platform for antibody therapies.

Dr. Cashman's discovery will allow Cangene to advance an immune therapeutic treatment approach to Alzheimer's by targeting the toxic form of Amyloid-beta with the potential to directly impact the disease mechanism of action.

Current treatment options are limited and the number of individuals afflicted with this degenerative disease is growing rapidly as the population ages, currently estimated to be 25 million worldwide.

"We are pleased to have the opportunity to collaborate with Dr. Cashman who is an expert in misfolded protein diseases and help advance his ground-breaking research in Alzheimer's Disease" says Dr. Laura Saward, Cangene's Chief Scientific Officer.

"While this work is in its early stages, it is showing promise for the development of a novel immunotherapy to address this devastating disease and fits Cangene's refocused strategy" adds Dr. Saward.

The Canadian Institute for Health Research (CIHR) is an important sponsor of the Alzheimer's Disease program. The discoveries made by Dr. Cashman were supported by research funding through CIHR and further advanced through a research collaboration between UBC, the federally-funded Prionet Network Centre of Excellence and Cangene, UBC's pharmaceutical industry partner.

UBC and Cangene continue to collaborate on the development of treatments for Alzheimer's Disease with support from CIHR's Proof of Principle Program Phase II.

The joint research program to evaluate the therapeutic potential of the target as a vaccine or antibody therapeutic was successful in the latest competition and CIHR has committed to provide $300,000 in funding over a one year period further cementing this as a made-in-Canada solution that has the potential to address this global problem.

"This is an all-Canadian solution in terms of its discovery, development and advancement towards the clinic," says Dr. J.P. Heale, Associate Director of UBC's University-Industry Liaison Office. "The partnerships developed to advance Dr. Cashman's outstanding research are an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!